HEXA and Tay-Sachs disease: Since many of the TSD-causative mutations do not compromise the catalytic site, but target the α chain of HexA to endoplasmic reticulum-associate degradation (ERAD), the development of pharmacological chaperones (PCs) that can stabilise the native folding of the protein despite its anomalous conformation and restore activity appears attractive.15